Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1991-12-16
1992-09-01
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530308, 530324, A61K 3728, C07K 710, C07K 734
Patent
active
051439026
ABSTRACT:
Glucagon analogs characterized principally by the removal of the 9-aspartic acid residue or its replacement with an amino acid residue other than an L- dibasic amino acid containing up to five carbon atoms with or without a histidine at the amino terminal are useful adjuncts to insulin therapy.
REFERENCES:
patent: 4879273 (1989-11-01), Merrifield
Jour. of Bio. Chem. vol. 259, issue on Jun. 10, pp. 7031-7037, 1984, Semisynthetic Derivatives of Glucagon, Flanders, et al.
Merrifield Robert B.
Unson Cecilia G.
Burke Henry T.
Cashion Jr. Merrell C.
Marshall S. G.
The Rockefeller University
LandOfFree
Glucagon analogs with ASP.sup.9 replacements or deletions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon analogs with ASP.sup.9 replacements or deletions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon analogs with ASP.sup.9 replacements or deletions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-767775